Pharming Group (CHIX:PHARMa)

€ 0.7515 0 (0%) Market Cap: 501.38 Mil Enterprise Value: 468.90 Mil PE Ratio: 0 PB Ratio: 2.69 GF Score: 81/100

Q1 2024 Pharming Group NV Earnings Call Transcript
May 08, 2024

€1.05

Earnings
Q4 2023 Pharming Group NV Earnings Call Transcript
Mar 14, 2024

€1.05

Earnings
Q3 2023 Pharming Group NV Earnings Call Transcript
Oct 26, 2023

€1.14

Earnings
Q2 2023 Pharming Group NV Earnings Call Transcript
Aug 03, 2023

€1.08

Earnings
Pharming Group NV Annual Shareholders Meeting Transcript
May 17, 2023
Q1 2023 Pharming Group NV Earnings Call Transcript
May 11, 2023

€1.13

Earnings
Pharming Group NV Corporate Analyst Meeting Transcript
Mar 27, 2023
Q4 2022 Pharming Group NV Earnings Call Transcript
Mar 16, 2023

€1.07

Earnings
Q3 2022 Pharming Group NV Earnings Call Transcript
Oct 27, 2022

€1.26

Earnings
Q2 2022 Pharming Group NV Earnings Call Transcript
Aug 04, 2022

€0.761

Earnings
Q1 2022 Pharming Group NV Earnings Call Transcript
May 12, 2022

€0.8535

Earnings
Q4 2021 Pharming Group NV Earnings Call Transcript
Mar 24, 2022

€0.891

Earnings
Q4 2021 Pharming Group NV Earnings Call Transcript
Mar 17, 2022

€0.891

Earnings
Pharming Group NV Announces Leniolisib Results Call Transcript
Feb 03, 2022
Q3 2021 Pharming Group NV Earnings Call Transcript
Oct 28, 2021

€0.7854

Earnings
Q2 2021 Pharming Group NV Earnings Call Transcript
Aug 05, 2021

€1

Earnings
Pharming Group NV and Orchard Therapeutics PLC Announce Collaboration to Develop and Commercialize Ex Vivo Autologous HSC Gene Therapy for Hereditary Angioedema Call Transcript
Jul 01, 2021
Pharming Group NV Annual Shareholders Meeting Transcript
May 19, 2021
Q1 2021 Pharming Group NV Earnings Call Transcript
May 13, 2021

€1.08

Earnings
Q4 2020 Pharming Group NV Earnings Call Transcript
Mar 04, 2021

€1.12

Earnings

Q4 2022 Pharming Group NV Earnings Call Transcript

Mar 16, 2023 / 12:30PM GMT

Release Date Price: €1.07

Transcript

Operator

Hello, and welcome to today's Pharming's Full Year 2022 Results Call. My name is Bailey, and I'll be the moderator for today's call. (Operator Instructions) I would now like to pass the conference over to your host, Sijmen de Vries, Chief Executive Officer. Please go ahead.

Sijmen de Vries

Pharming Group N.V. - President, CEO & Executive Director

Thank you very much, Bailey. Good morning or good afternoon, ladies and gentlemen, to our 2022 results call. I would like to start taking you through that.

But before I do that, I would like to -- you to pay attention to the next slide, which contains a statement on forward-looking -- on forward-looking statements, as we may be making forward-looking statements in this conversation. They are statements based upon our expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements, and you can read the rest for yourself, I assume.

I'm today here

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.